Download Clinical and Immunologic Assessment of Patients With Psoriasis in a

From: Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind,
Placebo-Controlled Trial Using Recombinant Human Interleukin 10
Arch Dermatol. 2002;138(10):1341-1346. doi:10.1001/archderm.138.10.1341
Figure Legend:
Recombinant human interleukin 10 (rhIL-10) leads to transient clinical improvement. Representative clinical photographs of an rhIL10–treated patient showing significant improvement at week 6 (Psoriasis Area Severity Index [PASI] score = 6.6) compared with
baseline (PASI score = 31.8) and disease flare at week 12 (PASI score = 19.1).
Date of download: 4/30/2017
Copyright © 2002 American Medical
Association. All rights reserved.
From: Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind,
Placebo-Controlled Trial Using Recombinant Human Interleukin 10
Arch Dermatol. 2002;138(10):1341-1346. doi:10.1001/archderm.138.10.1341
Figure Legend:
Patient disposition. rhIL-10 indicates recombinant human interleukin 10; FDA, US Food and Drug Administration.
Date of download: 4/30/2017
Copyright © 2002 American Medical
Association. All rights reserved.
From: Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind,
Placebo-Controlled Trial Using Recombinant Human Interleukin 10
Arch Dermatol. 2002;138(10):1341-1346. doi:10.1001/archderm.138.10.1341
Figure Legend:
Recombinant human interleukin 10 (rhIL-10) leads to decreases in platelet counts, hemoglobin levels, and cholesterol levels and
increases in serum IgE levels. Absolute mean values ± SEMs for either rhIL-10–treated (closed diamonds or closed bars) or
placebo-treated (open circles or open bars) patients during the study are shown. To convert cholesterol to millimoles per liter,
multiply by 0.0259.
Date of download: 4/30/2017
Copyright © 2002 American Medical
Association. All rights reserved.
From: Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind,
Placebo-Controlled Trial Using Recombinant Human Interleukin 10
Arch Dermatol. 2002;138(10):1341-1346. doi:10.1001/archderm.138.10.1341
Figure Legend:
Recombinant human interleukin 10 (rhIL-10) leads to decreased production of type 1 and proinflammatory cytokines by peripheral
blood CD4+ T cells and monocytes. Peripheral blood mononuclear cells were collected at 0 (baseline), 6, and 12 weeks in the study,
frozen, thawed, and restimulated with 4-α-phorbol 12-myristate 13-acetate and ionomycin. Intracellular cytokine production was
quantified using monoclonal antibody staining and flow cytometry. A, Representative dot plots from a single patient receiving rhIL-10
+ T cells throughout 12 weeks. B, Mean IFN-γ/IL-4
showing decreased interferon γ (IFN-γ) and increased
IL-4
by CD4
Copyright
© production
2002 American
Medical
+
Date
of
download:
4/30/2017
production ratio in CD4 T cells throughout 12 weeks,
using the
week 0 (baseline) as 100% (left panel). Mean percentage of
Association.
Allratio
rightsatreserved.
+
CD4 T cells or monocytes producing tumor necrosis factor α (TNF-α) throughout 12 weeks, using the percentage of cells at week 0